Liquid formulation of Vimpat relaunched

The antiepileptic Vimpat (lacosamide) has been relaunched by UCB Pharma and is now formulated as a lower strength syrup.

Vimpat syrup is unsuitable for patients with phenylketonuria
Vimpat syrup is unsuitable for patients with phenylketonuria

Vimpat (lacosamide) 10mg/ml syrup is indicated for the adjunctive treatment of partial onset-seizures with or without secondary generalisation in adults and children 16 years of age and older. The 10mg/ml syrup replaces the previous 15mg/ml formulation, which was recalled in 2011.

View Vimpat Syrup drug record

Further information: UCB Pharma Ltd

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Quadruple therapy should be 'new therapeutic standard' for heart failure, say researchers

Treatment with a four-drug regimen incorporating newer...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients